Completing data — refresh the page later to see the latest
1189944-95-3Cc1cc(C)cc(OCC2CNC(=O)O2)c1IMWZZHHPURKASS-UHFFFAOYSA-NMetaxalone is an aromatic ether.
1189944-95-3CHEMBL1079604CHEBI:6797White to almost white crystalline powder
Crystals from ethyl acetate
Freely soluble in chloroform; soluble in methanol and 95% ethanol; practically insoluble in ether
Practically insoluble in water
1.28e+00 g/L
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Pharmaceuticals
122 °C
122 °C
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
Warning
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 46 reports by companies from 2 notifications to the ECHA C&L Inventory.
The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, including metaxalone, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.
SRP: Expired or waste pharmaceuticals shall carefully take into consideration applicable DEA, EPA, and FDA regulations. It is not appropriate to dispose by flushing the pharmaceutical down the toilet or discarding to trash. If possible return the pharmaceutical to the manufacturer for proper disposal being careful to properly label and securely package the material. Alternatively, the waste pharmaceutical shall be labeled, securely packaged and transported by a state licensed medical waste contractor to dispose by burial in a licensed hazardous or toxic waste landfill or incinerator.
SRP: At the time of review, regulatory criteria for small quantity disposal are subject to significant revision, however, household quantities of waste pharmaceuticals may be managed as follows: Mix with wet cat litter or coffee grounds, double bag in plastic, discard in trash.
Metaxalone is a skeletal muscle relaxant indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions. The mode of action of this drug has not been clearly identified, but may be related to its sedative properties. Metaxalone does not directly relax tense skeletal muscles in man.
The mechanism of action of metaxalone in humans has not been established, but may be due to general central nervous system depression.
Metaxalone is a CNS depressant that has sedative and skeletal muscle relaxant effects. The precise mechanism of action of the drug is not known. The skeletal muscle relaxant effects of orally administered metaxalone are minimal and are probably related to its sedative effect. The drug does not directly relax skeletal muscle and, unlike neuromuscular blocking agents, does not depress neuronal conduction, neuromuscular transmission, or muscle excitability.
The mechanism of action of metaxalone in humans has not been established, but may be due to general central nervous system depression. Metaxalone has no direct action on the contractile mechanism of striated muscle, the motor end plate or the nerve fiber.
9.2 (+/- 4.8) hours
Terminal half-life /is/ 9.0 + or - 4.8 hours
Probably hepatic.
Biotransformations...studied in dogs and in man. 5-(3-methyl-5-carboxyphenoxymethyl)-2-oxazolidinone, major metabolite, is excreted in urine and feces; this also occurs in urine as ester glucuronide. Fission of ether linkage...affords...3,5-xylenol and 5-hydroxymethyloxazolidinone. Oxazolidinone ring is stable in mammals.
Yields 5-(5-carboxy-3-methylphenoxymethyl)-2-oxazolidone in man & in dogs, yields 3,5-dimethylphenol in man and in dogs. /From table/
Metaxalone is metabolized by the liver and excreted in the urine as unidentified metabolites.
152.3 Ų [M+Na]+ [CCS Type: DT; Buffer gas: N2; Ionization: ESI+; Dataset: TOXCAST; Source Identifier: DTXSID3023269]
152.15 Ų [M+K]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
According to the product brochure, metaxalone may cause jaundice, although there are no specific case reports of hepatotoxicity from metaxalone in the literature and no prospective trials with routine monitoring of aminotransferase levels. Given its long history, metaxalone appears to be without significant hepatotoxicity.
TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 530(SRC), determined from a structure estimation method(2), indicates that metaxalone is expected to have low mobility in soil(SRC). Volatilization of metaxalone from moist soil surfaces is not expected to be an important fate process(SRC) given an estimated Henry's Law constant of 2.7X10-10 atm-cu m/mole(SRC), using a fragment constant estimation method(3). Metaxalone is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 4.4X10-6 mm Hg at 25 °C(SRC), determined from a fragment constant method(4). Biodegradation data were not available(SRC, 2010).
AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 530(SRC), determined from a structure estimation method(2), indicates that metaxalone is expected to adsorb to suspended solids and sediment(SRC). Volatilization from water surfaces is not expected(3) based upon an estimated Henry's Law constant of 2.7X10-10 atm-cu m/mole(SRC), developed using a fragment constant estimation method(4). According to a classification scheme(5), an estimated BCF of 24(SRC), from an estimated log Kow of 2.6(6) and a regression-derived equation(7), suggests the potential for bioconcentration in aquatic organisms is low(SRC). Biodegradation data were not available(SRC, 2010).
ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), metaxalone, which has an estimated vapor pressure of 4.4X10-6 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), will exist in both the vapor and particulate phases in the ambient atmosphere. Vapor-phase metaxalone is degraded in the atmosphere by reaction with photochemically-produced hydroxyl radicals(SRC); the half-life for this reaction in air is estimated to be 2.2 hours(SRC), calculated from its rate constant of 1.7X10-10 cu cm/molecule-sec at 25 °C(SRC) that was derived using a structure estimation method(3). Particulate-phase metaxalone may be removed from the air by wet or dry deposition(SRC). Metaxalone does not contain chromophores that absorb at wavelengths >290 nm(4), and therefore is not expected to be susceptible to direct photolysis by sunlight(SRC).
Metaxalone was detected in one of three wastewater treatment plant effluents associated with facilities involved in the manufacture of pharmaceuticals in New York; 35-38 samples were collected from each plant between 2004 and 2009. The concentration of metaxalone was 3,800 ug/L in the one New York sample, which receives 20% of its discharge from a pharmaceutical formulation facility. The median concentration ranged from 0.5 to >400 ug/L. It was not detected in twenty-three plants across the US were analyzed once between 2004 and 2009 as part of a National Survey; more than half of these plants receive hospital discharge. Detection limit = 0.011 ug/L. These findings suggest that current manufacturing practices at pharmaceutical formulation facilities can result in pharmaceuticals concentrations from 10 to 1000 times higher than those typically found in wastewater treatment plant effluents(1).
Using a structure estimation method based on molecular connectivity indices(1), the Koc of metaxalone can be estimated to be 530(SRC). According to a classification scheme(2), this estimated Koc value suggests that metaxalone is expected to have low mobility in soil.
/CASE REPORTS/ A 29-year old female with a history of depression was found dead in a hotel room. The death scene investigation found empty pill bottles and an empty liter bottle of wine. Metaxalone, a centrally acting muscle relaxant, along with citalopram, ethanol, and chlorpheniramine were identified in the postmortem samples and quantitated by gas chromatography-mass spectrometry. The concentration of metaxalone in femoral vein blood was 39 mg/L. The heart blood concentration was 54 mg/L. Femoral vein blood concentrations of citalopram and chlorpheniramine were 0.77 mg/L and 0.04 mg/L, respectively. Ethanol levels were 0.13 g/dL in vitreous and 0.08 g/dL in heart blood. Other tissue samples were also analyzed. The authors consider the metaxalone concentrations toxic and potentially fatal. The citalopram concentrations were lower than those reported in fatal cases for this drug alone. Death was ascribed to polydrug abuse/overdose with metaxalone a major contributor. This represents the first reported case to our knowledge in which a metaxalone overdose significantly contributed to death.
/CASE REPORTS/ A case is presented of a 54-year-old white female found dead in a secured apartment. Postmortem toxicologic analysis of the heart blood identified acetaminophen (97 mg/L), citalopram (0.4 mg/L), gabapentin (24 mg/L) and metaxalone (21 mg/L). The metaxalone concentration is within the range of previously reported fatalities involving metaxalone. The medical examiner ruled that the cause of death was metaxalone and gabapentin intoxication and the manner of death was suicide.
/SURVEILLANCE/ The purpose of this study was to describe the pattern of metaxalone ingestions by young children reported to poison control centers. METHODS: Cases were all metaxalone ingestions by patients aged 0 to 5 years reported to Texas poison control centers during 2000 to 2007. Cases with multiple substance ingestions and lack of follow-up were excluded. Cases were analyzed for selected demographic and clinical factors. Of 148 total cases, 56.8% were boys. The distributions by management site were 56.1% on-site, 22.3% already at/en route to a health care facility, and 21.6% referred to a health care facility. Final medical outcomes were no effect for 90.5% cases, minor effect for 8.1%, moderate effect for 0.7%, and major effect for 0.7%. Specific clinical effects reported were drowsiness (11), vomiting (3), agitation (2), rash (1%), tachycardia (1), and ataxia (1). Pediatric metaxalone ingestions reported to Texas poison control centers usually resulted in minor or no effect. Most ingestions did not require hospitalization.
/SURVEILLANCE/ Few data exist on potentially adverse metaxalone ingestions in adults. All metaxalone ingestions involving patients aged > or = 20 years during 2000-2006 were retrieved from Texas poison control centers. Exclusion criteria were lack of follow-up or multiple substance ingestion. Cases were analyzed for selected demographic and clinical factors. Of the 142 patients, 66.2% were female. Dose ingested was reported for 61 patients. Of those cases with a reported dose, distribution by management site was 29.5% on-site, 59.0% already at/en route to health care facility, and 11.5% referred to health care facility. Final medical outcome was 'no effect' for 50.8% cases, 'minor effect' for 31.1%, and 'moderate effect' for 18.0%. The more common adverse clinical effects reported were drowsiness (27.9%), tachycardia (6.6%), agitation (6.6%), nausea (4.9%), dizziness (4.9%), slurred speech (4.9%), and tremor (4.9%). A moderate medical outcome occurred in 13.6% of ingestions of <or=2400 mg and 20.5% of ingestions of >2400 mg. Management involved a health care facility in 18.2% of ingestions of <or=2400 mg and 100.0% of ingestions of >2400 mg. This study found that adult ingestions of higher doses of metaxalone, particularly >2400 mg, were associated with more serious medical outcomes and were managed at health care facilities.
Drug Induced Liver Injury Rank (DILIrank 2.0)
Metaxalone
vLess-DILI-concern
5
Adverse reactions
DOI:10.1016/j.drudis.2016.02.015
An estimated BCF of 24 was calculated in fish for metaxalone(SRC), using an estimated log Kow of 2.60(1) and a regression-derived equation(2). According to a classification scheme(3), this BCF suggests the potential for bioconcentration in aquatic organisms is low(SRC).
The Henry's Law constant for metaxalone is estimated as 2.7X10-10 atm-cu m/mole(SRC) using a fragment constant estimation method(1). This Henry's Law constant indicates that metaxalone is expected to be essentially nonvolatile from water surfaces(2). Metaxalone's Henry's Law constant indicates that volatilization from moist soil surfaces may not occur(SRC). Metaxalone is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 4.4X10-6 mm Hg(SRC), determined from a fragment constant method(3).
/LABORATORY ANIMALS: Acute Exposure/ In dogs, no LD50 could be determined as the higher doses produced an emetic action in 15 to 30 minutes.
/LABORATORY ANIMALS: Acute Exposure/ When determining the LD50 in rats and mice, progressive sedation, hypnosis and finally respiratory failure were noted as the dosage increased.
The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, including metaxalone, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.
1NMA9J598Y
METAXALONE
Physiologic Effects [PE] - Centrally-mediated Muscle Relaxation
Established Pharmacologic Class [EPC] - Muscle Relaxant
Metaxalone is a Muscle Relaxant. The physiologic effect of metaxalone is by means of Centrally-mediated Muscle Relaxation.
METAXALONE
Drugs used for their actions on skeletal muscle. Included are agents that act directly on skeletal muscle, those that alter neuromuscular transmission (NEUROMUSCULAR BLOCKING AGENTS), and drugs that act centrally as skeletal muscle relaxants (MUSCLE RELAXANTS, CENTRAL). Drugs used in the treatment of movement disorders are ANTI-DYSKINESIA AGENTS.
The absolute bioavailability of metaxalone from Skelaxin tablets is not known.
Metaxalone is metabolized by the liver and excreted in the urine as unidentified metabolites.
800 L
68 +/- 50 L/h [Subjects received 1×400mg tablet under fasted conditions]
Although plasma protein binding and absolute bioavailability of metaxalone are not known, the apparent volume of distribution (V/F ~ 800 L) and lipophilicity (log P = 2.42) of metaxalone suggest that the drug is extensively distributed in the tissues. Metaxalone is metabolized by the liver and excreted in the urine as unidentified metabolites.
Peak plasma concentrations of metaxalone occur approximately 3 hours after a 400 mg oral dose under fasted conditions. Thereafter, metaxalone concentrations decline log-linearly with a terminal half-life of 9.0 + or - 4.8 hours. Doubling the dose of skelaxin from 400 mg to 800 mg results in a roughly proportional increase in metaxalone exposure as indicated by peak plasma concentrations (Cmax) and area under the curve (AUC). Dose proportionality at doses above 800 mg has not been studied. The absolute bioavailability of metaxalone is not known
MEDICATION
Use (kg) in USA (2002): 115000
LUNSFORD ET AL, J AM CHEM SOC 82, 1166 (1960); LUNSFORD, US PAT 3,062,827 (1962 TO AH ROBINS).
Prepared by heating urea and 3-(3',5'-dimethylphenoxy)-1,2-propanediol to 200 °C
UsesIt is a muscle relaxant used to relax muscles and relieve pain.
Uses(Metaxalone D6) Labeled Metaxalone, intended for use as an internal standard for the quantification of Metaxalone by GC- or LC-mass spectrometry.
For more Human Toxicity Excerpts (Complete) data for METAXALONE (6 total), please visit the HSDB record page.